Kashiv BioSciences, LLC declared the start of enrollment for their Phase III clinical trial initiating with their first patient for their biosimilar candidate, ADL018, a potential alternative to XOLAIR®.

This article summarized the latest R&D progress of bupivacaine hydrochloride, the Mechanism of Action for bupivacaine hydrochloride, and the drug target R&D trends for bupivacaine hydrochloride.

Nexcella Inc. revealed updates from its ongoing Phase 1b/2 NEXICART-1 trial on its proprietary BCMA-targeted CAR T cell treatment, NXC-201.

Recombinant protein refers to the protein obtained using recombinant DNA or RNA technology.

Novartis reported promising initial results from a 9-month interim assessment of the Phase III APPLAUSE-IgAN trial. The experimental factor B inhibitor, iptacopan, showed superior effectiveness in reducing proteinuria compared to placebo.

This article summarized the latest R&D progress of bromfenac sodium, the Mechanism of Action for bromfenac sodium, and the drug target R&D trends for bromfenac sodium.

Biogen Inc. disclosed that the U.S. FDA provided their endorsement for TOFIDENCE (tocilizumab-bavi) in an intravenous format, a biosimilar monoclonal antibody that references ACTEMRA.

Interleukins (IL), also known as "white cell stimulators," are a type of cytokines first found to be produced by white blood cells and act between them.

AbbVie shared Phase 3 CANOVA trial results for the VenDex combo in treating relapsed or resistant multiple myeloma in patients with two or more prior treatments.

This article summarized the latest R&D progress of brimonidine tartrate/timolol maleate, the Mechanism of Action for brimonidine tartrate/timolol maleate, and the drug target R&D trends for brimonidine tartrate/timolol maleate.

JCR Pharmaceuticals Co., Ltd. has disclosed critical findings from the midway 52-week data of its global research phase I/II involving JR-171 (lepunafusp alfa) in patients diagnosed with mucopolysaccharidosis type I.

This article summarized the latest R&D progress of alverine citrate, the Mechanism of Action for alverine citrate, and the drug target R&D trends for alverine citrate.